265 related articles for article (PubMed ID: 29784193)
21. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
23. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.
Karakiewicz PI; Zaffuto E; Kapoor A; Basappa NS; Bjarnason GA; Blais N; Breau RH; Canil C; Drachenberg D; Hotte SJ; Jeldres C; Jewett MAS; Kassouf W; Kollmannsberger C; Lavallée LT; Maloni R; Patenaude F; Pouliot F; Reaume MN; Sabbagh R; Shayegan B; So A; Soulières D; Tanguay S; Wood L; Bandini M
Can Urol Assoc J; 2018 Jun; 12(6):173-180. PubMed ID: 29877179
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
25. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
Fallara G; Bandini M; Larcher A; Pederzoli F; Karakiewicz P; Tian Z; Briganti A; Necchi A; Salonia A; Bertini R; Montorsi F; Bex A; Capitanio U
Curr Probl Cancer; 2021 Dec; 45(6):100759. PubMed ID: 34130863
[TBL] [Abstract][Full Text] [Related]
26. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
29. A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma.
Guo L; An T; Huang Z; Chong T
BMC Urol; 2024 Mar; 24(1):55. PubMed ID: 38454397
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Wei C; Wang S; Ye Z; Chen Z
Int Braz J Urol; 2018; 44(2):219-237. PubMed ID: 29211397
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
Riaz IB; Faridi W; Husnain M; Malik SU; Sipra QUAR; Gondal FR; Xie H; Yadav S; Kohli M
Mayo Clin Proc; 2019 Aug; 94(8):1524-1534. PubMed ID: 31303430
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
36. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.
Ravaud A
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():12-17. PubMed ID: 32852898
[TBL] [Abstract][Full Text] [Related]
38. Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Donskov F; Escudier B; Li S; Casey M; Valota O; Laguerre B; Pantuck AJ; Pandha HS; Patel A; Lechuga M; Ravaud A
Clin Cancer Res; 2019 Feb; 25(4):1165-1173. PubMed ID: 30401688
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
